Andrew Dobrotwir1, Emma Pun. 1. Department of Radiology, The Royal Women's Hospital, Melbourne, Victoria, Australia.
Abstract
AIM: To describe and evaluate treatment of uterine fibroids using Magnetic Resonance Guided Focused Ultrasound (MRgFUS) during its first 24 months of use at The Royal Women's Hospital Melbourne. METHODS: One hundred Victorian women were treated with MRgFUS using the ExAblate 2000 system. Treatment outcomes based on fibroid volume shrinkage measured at 4 and 12 months post-treatment and symptom severity score assessment (Symptom Severity Score Quality of Life - SSS-QOL) pre- and post- (4-6 weeks, 4, 6 and 12 months) treatment. RESULTS: Mean non-perfused volume of the treated fibroids were 67% ± 25% (n = 100) immediately post-treatment. At 4 months post-treatment, the treated fibroids demonstrated an average volume reduction of 29% ± 32% (n = 74) and at 12 months 38% ± 45% (n = 32). Mean symptom severity scores (SSS-QOL) improved by 51% from 59 ± 21 (n = 97) at baseline to 29 ± 17 (n = 36) by 12 months. CONCLUSION: From our experience, we believe there is a role for MRgFUS in the treatment of uterine fibroids in selected women.
AIM: To describe and evaluate treatment of uterine fibroids using Magnetic Resonance Guided Focused Ultrasound (MRgFUS) during its first 24 months of use at The Royal Women's Hospital Melbourne. METHODS: One hundred Victorian women were treated with MRgFUS using the ExAblate 2000 system. Treatment outcomes based on fibroid volume shrinkage measured at 4 and 12 months post-treatment and symptom severity score assessment (Symptom Severity Score Quality of Life - SSS-QOL) pre- and post- (4-6 weeks, 4, 6 and 12 months) treatment. RESULTS: Mean non-perfused volume of the treated fibroids were 67% ± 25% (n = 100) immediately post-treatment. At 4 months post-treatment, the treated fibroids demonstrated an average volume reduction of 29% ± 32% (n = 74) and at 12 months 38% ± 45% (n = 32). Mean symptom severity scores (SSS-QOL) improved by 51% from 59 ± 21 (n = 97) at baseline to 29 ± 17 (n = 36) by 12 months. CONCLUSION: From our experience, we believe there is a role for MRgFUS in the treatment of uterine fibroids in selected women.
Authors: Giovanni Mauri; Luca Nicosia; Zhen Xu; Salvatore Di Pietro; Lorenzo Monfardini; Guido Bonomo; Gianluca Maria Varano; Francesco Prada; Paolo Della Vigna; Franco Orsi Journal: Br J Radiol Date: 2018-01-17 Impact factor: 3.039
Authors: Inez M Verpalen; Jolien P de Boer; Marlot Linstra; Roelien L I Pol; Ingrid M Nijholt; Chrit T W Moonen; Lambertus W Bartels; Arie Franx; Martijn F Boomsma; Manon N G Braat Journal: Eur Radiol Date: 2020-02-10 Impact factor: 5.315
Authors: Alissa Hendricks-Wenger; Lauren Arnold; Jessica Gannon; Alex Simon; Neha Singh; Hannah Sheppard; Margaret A Nagai-Singer; Khan Mohammad Imran; Kiho Lee; Sherrie Clark-Deener; Christopher Byron; Michael R Edwards; Martha M Larson; John H Rossmeisl; Sheryl L Coutermarsh-Ott; Kristin Eden; Nikolaos Dervisis; Shawna Klahn; Joanne Tuohy; Irving Coy Allen; Eli Vlaisavljevich Journal: IEEE Trans Ultrason Ferroelectr Freq Control Date: 2021-12-31 Impact factor: 3.267
Authors: Bijan J Borah; Ginger S Carls; Brian J Moore; Teresa B Gibson; James P Moriarty; Elizabeth A Stewart Journal: J Ther Ultrasound Date: 2014-03-31